

bioMerieux SA (BIM) - Financial and Strategic SWOT Analysis Review

https://marketpublishers.com/r/B7AB2413B37EN.html

Date: June 2021

Pages: 66

Price: US\$ 125.00 (Single User License)

ID: B7AB2413B37EN

Abstracts

bioMerieux SA (BIM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description – A detailed description of the company's operations and business divisions.

Corporate strategy – Analyst's summarization of the company's business strategy.

SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history – Progression of key events associated with the company.

Major products and services – A list of major products, services and brands of the company.

Key competitors – A list of key competitors to the company.

Key employees – A list of the key executives of the company.



Executive biographies – A brief summary of the executives' employment history.

Key operational heads – A list of personnel heading key departments/functions.

Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

bioMerieux SA (bioMerieux), a subsidiary of Institut Merieux SA, develops, manufactures, and markets in vitro diagnostic solutions for hospital and private laboratories. The company offers diagnostic solutions such as systems, reagents, and software for the diagnosis of infectious diseases, cardiovascular diseases, and cancers and identifying microorganisms in pharmaceuticals, cosmetics, and agri-food products. It offers microbiology products, immunoassays, molecular biology tests, and other solutions for clinical applications and industrial microbiological control solutions for the food, biopharmaceutical, and cosmetics industries; veterinary diagnostic laboratories; and blood banks. bioMerieux also provides solutions for the enumeration of bacterial flora which indicate the quality of food products. The company distributes its products directly and through a network of distributors across the world. bioMerieux is headquartered in Marcy l'Etoile, France.

bioMerieux SA Key Recent Developments

Feb 24,2021: bioMerieux – 2020 financial results

Dec 14,2020: BioMerieux – Increased outlook for full-year 2020 Oct 22,2020: bioM?rieux – third-quarter 2020 business review

Oct 08,2020: AMSP partners with bioM?rieux to facilitate supply of high-quality



COVID-19 diagnostics

Sep 30,2020: Johnson & Johnson joins other companies in signing a landmark Communiqu? on expanded global access for COVID-19

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.



Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company



Contents

SECTION 1 - ABOUT THE COMPANY

bioMerieux SA - Key Facts

bioMerieux SA - Key Employees

bioMerieux SA - Key Employee Biographies

bioMerieux SA - Major Products and Services

bioMerieux SA - History

bioMerieux SA - Company Statement

bioMerieux SA - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview

bioMerieux SA - Business Description

Business Segment: Clinical Applications

Overview

Performance

Business Segment: Industrial Applications

Overview

Performance

Geographical Segment: Americas

Performance

Geographical Segment: Asia-Pacific

Performance

Geographical Segment: Europe, Middle East, and Africa

Performance R&D Overview

bioMerieux SA - Corporate Strategy

bioMerieux SA - SWOT Analysis

SWOT Analysis - Overview

bioMerieux SA - Strengths

bioMerieux SA - Weaknesses

bioMerieux SA - Opportunities

bioMerieux SA - Threats

bioMerieux SA - Key Competitors



SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios

Financial Ratios - Annual Ratios

Performance Chart

Financial Performance

Financial Ratios - Interim Ratios

Financial Ratios - Ratio Charts

SECTION 4 - COMPANY'S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

bioMerieux SA, Medical Equipment, Deals By Year, 2015 to YTD 2021 bioMerieux SA, Medical Equipment, Deals By Type, 2015 to YTD 2021 bioMerieux SA, Recent Deals Summary

SECTION 5 – COMPANY'S RECENT DEVELOPMENTS

Feb 24, 2021: bioMerieux – 2020 financial results

Dec 14, 2020: BioMerieux – Increased outlook for full-year 2020

Oct 22, 2020: bioM?rieux - third-quarter 2020 business review

Oct 08, 2020: AMSP partners with bioM?rieux to facilitate supply of high-quality

COVID-19 diagnostics

Sep 30, 2020: Johnson & Johnson joins other companies in signing a landmark

Communiqu? on expanded global access for COVID-19

Jul 09, 2020: bioM?rieux - Second quarter 2020 business performance

preannouncement

Jun 02, 2020: Teklynx labeling software teklynx central increases labeling accuracy &

compliance by 100% for global biotechnology company bioMerieux

Apr 16, 2020: bioM?rieux first-quarter 2020 business review

Mar 27, 2020: Novartis partners with life sciences companies to fight Covid-19

Mar 26, 2020: Novartis and life sciences companies commit expertise and assets to the

fight against COVID-19 pandemic alongside Bill & Melinda Gates Foundation

SECTION 6 – APPENDIX

Methodology Ratio Definitions About GlobalData



Contact Us Disclaimer



List Of Tables

LIST OF TABLES

bioMerieux SA, Key Facts

bioMerieux SA, Key Employees

bioMerieux SA, Key Employee Biographies

bioMerieux SA, Major Products and Services

bioMerieux SA, History

bioMerieux SA, Subsidiaries

bioMerieux SA, Key Competitors

bioMerieux SA, Ratios based on current share price

bioMerieux SA, Annual Ratios

bioMerieux SA, Annual Ratios (Cont...1)

bioMerieux SA, Annual Ratios (Cont...2)

bioMerieux SA, Interim Ratios

bioMerieux SA, Medical Equipment, Deals By Year, 2015 to YTD 2021

bioMerieux SA, Medical Equipment, Deals By Type, 2015 to YTD 2021

bioMerieux SA, Recent Deals Summary

Currency Codes

Capital Market Ratios

Equity Ratios

Profitability Ratios

Cost Ratios

Liquidity Ratios

Leverage Ratios

Efficiency Ratios



List Of Figures

LIST OF FIGURES

bioMerieux SA, Performance Chart (2016 - 2020)

bioMerieux SA, Ratio Charts

bioMerieux SA, Medical Equipment, Deals By Year, 2015 to YTD 2021

bioMerieux SA, Medical Equipment, Deals by Type, 2015 to YTD 2021



I would like to order

Product name: bioMerieux SA (BIM) - Financial and Strategic SWOT Analysis Review

Product link: https://marketpublishers.com/r/B7AB2413B37EN.html

Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/B7AB2413B37EN.html